FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298977> ?p ?o ?g. }

• W4286298977 endingPage "e18001" @default.
• W4286298977 startingPage "e18001" @default.
• W4286298977 abstract "e18001 Background: The efficacy and safety of Pembrolizumab in recurrent /unresectable/metastatic head and neck squamous cell carcinoma have been well documented in KEYNOTE-048 and other studies, and the effectiveness of different areas’ population have been shown in related studies. However, there is no native data based on the Chinese population. The purpose of this study was to investigate the efficacy and safety of Pembrolizumab in the treatment of R/U/M head and neck squamous cell carcinoma in Chinese population. Methods: We reviewed patients data from the department of Oral & Maxillofacial Surgery, the Affiliated Hospital of Qingdao University. The patients with R/U/M head and neck squamous cell carcinoma were treated with or without combined chemotherapy / targeted therapy according to their PD-L1 expression status (CPS). Pembrolizumab was infused intravenously with 200mg every 3 weeks for a maximum of 35 cycles. The primary endpoint was Objective Response Rate(ORR). The secondary endpoints were Quality of Life, Safety and Progression Free Survival(PFS). Results: A total of 23 eligible patients with R/U/M head and neck squamous cell carcinoma were included from February 2021 to February 2022, including 18 males (78.26%) and 5 females (21.74%) with a median age of 68 years. The primary sites were oral cavity in 16 cases (69.56%), oropharynx in 4 cases (17.39%), hypopharynx in 1 case (4.35%), and larynx in 2 cases (8.70%). P16 status was positive in 4 cases (17.39%), negative in 12 cases (52.17%), and unknown in 7 cases (30.43%). The expression status of PD-L1 in all patients was known. Patients with CPS ≥ 20 were treated with Pembrolizumab monotherapy and patients with CPS < 20 were treated with Pembrolizumab combined with chemotherapy / targeting therapy, of which 22 (95.65%) were treated with first-line therapy and 1 (4.35%) were treated with second-line therapy. The median follow-up period was 6 months. 15 patients were assessed as remission (as of February 2022), of which 4 (17.39%) showed CR, 11 (47.83%) showed PR, 7 (30.43%) showed SD, and 1 (4.35%) showed PD. ORR was 65.22%, DCR was 95.65%. After 4 cycles of treatment, 14 patients (60.87%) achieved tumor remission and control, and the functional status score (KPS) increased from 65 to 85. The incidences of thyroid dysfunction, skin rash, fatigue, neutropenia and immune pneumonia were 2 (8.70%), 3 (13.04%), 2 (8.70%), 1 (4.35%) and 1(4.35%), respectively. Conclusions: This retrospective data have shown excellent efficacy and safety of pembrolizumab in the Chinese population of R/U/M head and neck squamous cell carcinoma, and provide data support for follow-up related research.Due to the short follow-up time, most of the patients have not yet reached PFS, and follow-up will continue." @default.
• W4286298977 created "2022-07-21" @default.
• W4286298977 creator A5065825259 @default.
• W4286298977 creator A5068640768 @default.
• W4286298977 creator A5077001645 @default.
• W4286298977 creator A5091419308 @default.
• W4286298977 date "2022-06-01" @default.
• W4286298977 modified "2023-09-24" @default.
• W4286298977 title "Efficacy and safety of pembrolizumab in Chinese patients with recurrent/unresectable/metastatic head and neck squamous cell carcinoma." @default.
• W4286298977 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e18001" @default.
• W4286298977 hasPublicationYear "2022" @default.
• W4286298977 type Work @default.
• W4286298977 citedByCount "1" @default.
• W4286298977 countsByYear W42862989772022 @default.
• W4286298977 crossrefType "journal-article" @default.
• W4286298977 hasAuthorship W4286298977A5065825259 @default.
• W4286298977 hasAuthorship W4286298977A5068640768 @default.
• W4286298977 hasAuthorship W4286298977A5077001645 @default.
• W4286298977 hasAuthorship W4286298977A5091419308 @default.
• W4286298977 hasConcept C121608353 @default.
• W4286298977 hasConcept C126322002 @default.
• W4286298977 hasConcept C141071460 @default.
• W4286298977 hasConcept C143998085 @default.
• W4286298977 hasConcept C203092338 @default.
• W4286298977 hasConcept C2776530083 @default.
• W4286298977 hasConcept C2776694085 @default.
• W4286298977 hasConcept C2776833033 @default.
• W4286298977 hasConcept C2777701055 @default.
• W4286298977 hasConcept C2780057760 @default.
• W4286298977 hasConcept C2780474809 @default.
• W4286298977 hasConcept C2908647359 @default.
• W4286298977 hasConcept C535046627 @default.
• W4286298977 hasConcept C71924100 @default.
• W4286298977 hasConcept C99454951 @default.
• W4286298977 hasConceptScore W4286298977C121608353 @default.
• W4286298977 hasConceptScore W4286298977C126322002 @default.
• W4286298977 hasConceptScore W4286298977C141071460 @default.
• W4286298977 hasConceptScore W4286298977C143998085 @default.
• W4286298977 hasConceptScore W4286298977C203092338 @default.
• W4286298977 hasConceptScore W4286298977C2776530083 @default.
• W4286298977 hasConceptScore W4286298977C2776694085 @default.
• W4286298977 hasConceptScore W4286298977C2776833033 @default.
• W4286298977 hasConceptScore W4286298977C2777701055 @default.
• W4286298977 hasConceptScore W4286298977C2780057760 @default.
• W4286298977 hasConceptScore W4286298977C2780474809 @default.
• W4286298977 hasConceptScore W4286298977C2908647359 @default.
• W4286298977 hasConceptScore W4286298977C535046627 @default.
• W4286298977 hasConceptScore W4286298977C71924100 @default.
• W4286298977 hasConceptScore W4286298977C99454951 @default.
• W4286298977 hasIssue "16_suppl" @default.
• W4286298977 hasLocation W42862989771 @default.
• W4286298977 hasOpenAccess W4286298977 @default.
• W4286298977 hasPrimaryLocation W42862989771 @default.
• W4286298977 hasRelatedWork W2020319882 @default.
• W4286298977 hasRelatedWork W2020823099 @default.
• W4286298977 hasRelatedWork W2142498781 @default.
• W4286298977 hasRelatedWork W2354390866 @default.
• W4286298977 hasRelatedWork W2954897945 @default.
• W4286298977 hasRelatedWork W2963491961 @default.
• W4286298977 hasRelatedWork W3000701650 @default.
• W4286298977 hasRelatedWork W3090002302 @default.
• W4286298977 hasRelatedWork W3103265772 @default.
• W4286298977 hasRelatedWork W4283523414 @default.
• W4286298977 hasVolume "40" @default.
• W4286298977 isParatext "false" @default.
• W4286298977 isRetracted "false" @default.
• W4286298977 workType "article" @default.